VERU | tickerfilter.com

Fundamental analysis

26%

Profitability 0%

Dept financing 28%

Liquidity 72%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.29%

1 Month

9.40%

3 Months

-3.40%

6 Months

-24.04%

1 Year

384.66%

2 Year

298.75%

Key data

Stock price

$2.56

P/E Ratio

0.00

DAY RANGE

$2.49 - $2.63

EPS

-$0.71

52 WEEK RANGE

$0.36 - $4.59

52 WEEK CHANGE

$398.73

MARKET CAP

34.348 M

YIELD

N/A

SHARES OUTSTANDING

16.050 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

0.66

PUBLIC FLOAT

AVERAGE 10 VOLUME

$53,041

AVERAGE 30 VOLUME

$69,988

Company detail

CEO: Mitchell S. Steiner
Region: US
Website: verupharma.com
Employees: 230
IPO year: 1999

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Veru Inc. focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company was formerly known as The Female Health Company.

VERU - VERU INC.